On July 29th, Roche announced its readiness to immediately resume new orders and shipments of Elevidys for ambulatory patients outside the United States. This follows the FDA’s recommendation to lift the temporary pause on shipments for ambulatory individuals with Duchenne muscular dystrophy.
Based on a comprehensive review of the available data, Roche maintains that the benefit-risk profile of Elevidys remains positive in the ambulatory patient population. Roche continues to prioritise patient safety above all else.
The full community letter can be read here
If you would like to talk about the topic discussed in this article, please do reach out to us at info@actionduchenne.org.
Join us at the Action Duchenne Annual International Conference 2025 to find how we can support your family, and to hear the latest news from clinicians, on the 14th and 15th of November in Hinckley, Leicestershire!
Entrada Therapeutics Shares Update on Duchenne Muscular Dystrophy (DMD) Programs
